Endpoints News

Dizal’s first-line lung cancer data; Sanofi expands in China

Published

2 weeks ago

on

Plus, news about Opdivo:

📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line non-small cell lung cancer patients …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version